Spruce Biosciences to implement 1-for-75 reverse stock split

Published 25/07/2025, 05:48
Spruce Biosciences to implement 1-for-75 reverse stock split

SOUTH SAN FRANCISCO - Spruce Biosciences, Inc. (OTCQB:SPRB), currently trading with a market capitalization of $5.15 million, will implement a 1-for-75 reverse stock split of its common stock effective August 4, 2025, with trading on a split-adjusted basis beginning August 5, the company announced. According to InvestingPro data, the stock has shown significant price volatility, with a beta of 2.4.

The reverse split, approved by stockholders on July 22, aims to bring the late-stage biopharmaceutical company into compliance with Nasdaq Capital Market’s minimum bid price requirement. Spruce anticipates relisting on the Nasdaq if it maintains compliance for 20 consecutive trading days following the effective date. The company’s shares have experienced a challenging year, with InvestingPro showing a 71% decline year-to-date.

The split will reduce Spruce’s outstanding shares from approximately 42.2 million to 0.6 million shares, while maintaining the same trading symbol. Proportionate adjustments will be made to the company’s outstanding stock options, restricted stock unit awards, and warrants.

Stockholders will not receive fractional shares but instead will get cash payments for any fractional interests. Those holding shares electronically need not take action to receive post-split shares.

Computershare Inc. is serving as the exchange agent and transfer agent for the reverse stock split.

Spruce Biosciences describes itself as focused on developing therapies for neurological disorders with significant unmet medical need. The information in this article is based on a company press release statement.

In other recent news, Spruce Biosciences has received approval from Nasdaq to resume trading on the Nasdaq Capital Market. This approval is contingent upon the company regaining compliance with Nasdaq’s minimum bid price requirement by August 5, 2025. To address this requirement, Spruce Biosciences is seeking stockholder approval for a reverse stock split at its upcoming annual meeting on July 22. The company’s board has indicated that this measure is necessary to meet the exchange’s standards. These developments are part of the company’s ongoing efforts to maintain its listing status on Nasdaq.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.